Garth Lees-Rolfe - Apr 1, 2024 Form 3 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Chief Financial Officer
Signature
/s/ Garth Lees-Rolfe
Stock symbol
IKT
Transactions as of
Apr 1, 2024
Transactions value $
$0
Form type
3
Date filed
4/2/2024, 05:12 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IKT Stock Option (right to buy) Apr 1, 2024 Common Stock 5.83K $3.79 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the options vested and became exercisable on November 28, 2023. One-third of the options will vest and become exercisable on November 28, 2024 and one-third of the options will vest and become exercisable on November 28, 2025, in each case subject to continued employment through each such vesting date.
F2 The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.